All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Refana
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 10, 2020
Details:
Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: LAXAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Details:
Under this collaboration, A2A designed the molecules using its proprietary computational AI-enabled drug discovery platform SCULPT™, which are currently being synthesized and will be evaluated by Laxai.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nafamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Favipiravir will be marketed by Brinton Pharmaceuticals under the brand name Faviton. Faviton will be initially launched in 18 countries where Brinton has its own presence. In India, It will be launched once DCGI approval process is completed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
The trials come after a Chinese official told reporters last month that an active ingredient of the drug had been effective, with no obvious side effects, in helping coronavirus patients recover.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant triple antigen vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
Premas Biotech has adopted a three-pronged approach to develop multi subunit vaccine, using recombinantly expressed antigens Spike, Envelope, and Membrane proteins in multiple formats.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: The Department of Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 20, 2020
Details:
Funding to support Cadila Healthcare for advancing its DNA Vaccine candidate against SARS-CoV-2 and to Bharat Biotech for COVID-19 vaccine candidate utilising the inactivated rabies vector platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon alpha-2b
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Interferon alpha can potentially emerge as one of the treatment options for COVID 19; In vitro and in vivo studies suggest positive effects on COVID-19 Patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Active virosome vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: The Union science and technology ministry of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 12, 2020
Details:
The Union science and technology ministry will fund Seagull Biosolutions to develop a vaccine for Covid-19 which is expected to enter phase-1 trial in 18-20 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
Details:
Vopec Pharmaceuticals has received the NOC and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
